Variables | AE group (n = 14) | NAE group (n = 42) | p value |
---|---|---|---|
Serum CXCL10 (pg/ml) | 53.9 (18.9-210.1) | 74.9 (2.8-1493.8) | 0.291 |
Serum CCL17 (pg/ml) | 450.8 (29.4-1450) | 132.9 (5.3-1189) | 0.003** |
Serum IL-4 (pg/ml) | 14.0 (0.0-73.7) | 13.0 (0.0-43.9) | 0.036* |
Serum IL-13 (pg/ml) | 148.3 (0.0-974.7) | 144.6 (0.0-550.7) | 0.622 |
Serum TGF-β (ng/ml) | 23.4 (4.5-299.5) | 18.8 (1.7-172.2) | 0.272 |
Serum IFN-γ (pg/ml) | ND | ND |  |
Variables | AE group (n = 11) | NAE group (n = 37) | p value |
BALF CXCL10 (pg/ml) | 59.0 (24.1-160.4) | 83.7 (9.1-733.7) | 0.624 |
BALF CCL17 (pg/ml) | 8.1 (0.0-38.9) | 5.9 (0.0-32.9) | 0.233 |
BALF IL-4 (pg/ml) | ND | ND | Â |
BALF IL-13 (pg/ml) | 31.4 (0.0-241.2) | 68.7 (0.0-290.4) | 0.851 |
BALF TGF-β (ng/ml) | 0.0 (0.0-796.1) | 387.3 (0.0-1782) | 0.042* |
BALF IFN-γ (pg/ml) | ND | ND |  |